Additionally, 17 potential therapeutic targets (AKT1, CCND1, CASP3, CTNNB1, EGF, EGFR, ESR1, HIF1A, HSP90AA1, IL6, JUN, MYC, MAPK3, PTEN, STAT3, TP53, VEGFA) were directly related to the KEGG pathway “cancer” and linked to 30 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZJ6, CL2, ZJ10, ZJ12, ZJ2, DSL4, DSL5, DSL6, ZZS1, CF1, CF10, GC12, GC16, GC37, QYS3, SQ13, XYS24, CBM16; Table S2). This evidence concerns the gene KIR3DL2 and cancer.